NCT02914938 - A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2023

Conditions

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Follicular Lymphoma (FL)Marginal Zone B Cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)High Grade Non-Hodgkin's LymphomaMantle Cell Lymphoma (MCL)

Interventions

DRUG

ME-401

60 mg

DRUG

Rituximab

IV infusion 375 mg/m2

DRUG

Zanubrutinib

80 and 160 mg bid

Trial Locations (24)

10016

NYU Langone Laura & Isaac - Perlmutter Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering, Harrison

11553

Memorial Sloan Kettering, Uniondale

11725

Memorial Sloan Kettering, Commack

11794

Stony Brook, Stony Brook

33136

Sylvester Comprehensive Cancer Center (Univ of Miami School of Med), Miami

37240

Vanderbilt, Nashville

44195

Cleveland Clinic, Cleveland

53792

Carbone Cancer Center, Madison

73104

Stephenson Cancer Center, Oklahoma City

75390

University of Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

85724

University of Arizona, Tucson

92708

Compassionate Care, Corona

98026

Swedish Cancer Institute, Edmonds

98029

Swedish Cancer Institute, Issaquah

98104

Swedish Cancer Center, Seattle

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Dana Farber, Boston

07920

Memorial Sloan Kettering, Basking Ridge

07748

Memorial Sloan Kettering, Middletown

07645

Memorial Sloan Kettering, Montvale

Unknown

lstituto Oncologico della Svizzera ltaliana Ospedale Regionale Bellinzona e Valli CH, Bellinzona